GlobeNewswire

Mentari Therapeutics to Present at Upcoming Investor Conferences
09/11/2026
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (Nasdaq: MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that members of [...]
Neutrolis Doses First Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Phase 1b LIBERATE-I Trial of NTR-1011 and Will Present Phase 1a Data at ACR Convergence 2026
09/11/2026
Multi-cohort Phase 1b study evaluating NTR-1011, a first-in-class DNASE1L3 fusion protein designed to degrade Neutrophil Extracellular Traps (NETs), in patients with moderate-to-severe SLE and RA despite standard of [...]
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
09/11/2026
Submission advances ABP-450 biosimilar development program following recent FDA Type 2b meeting Planned CMAP study designed to generate clinical evidence comparing the neuromuscular activity of ABP-450 and BOTOX ® ; [...]
Adneuris Therapeutics Reaches Key Regulatory Milestone with FDA Submission of New Drug Application for Cebranopadol in Moderate-to-Severe Acute Pain
09/11/2026
If approved, cebranopadol would be the first dual NOP/MOP receptor (dual-NMR) agonist analgesic available for moderate-to-severe acute pain, introducing a novel mechanism of action to a treatment landscape in need of [...]
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
09/11/2026
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced that Zhen Li, Ph.D., [...]
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
09/11/2026
WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
09/11/2026
WATERTOWN, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and [...]
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
09/11/2026
New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes 1 associated with different patient responses to bezisterim treatment. Patients with a high-inflammatory [...]
R1 and Ascension Extend Partnership Through 2037 Leveraging Phare OS to Advance a Technology-First Revenue Cycle
09/11/2026
Long-term agreement supports Ascension’s efforts to simplify the financial experience for patients, reduce administrative demands, and give care teams more time to focus on those they serve CHICAGO, Nov. 09, 2026 (GLOBE [...]
Mereo BioPharma Reports Third Quarter 2026 Financial Results
09/11/2026
Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta (OI) Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine [...]
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
09/11/2026
New name and ticker reflect a mission-driven company with one purpose: developing medicine for people who want to quit smoking or vaping. If approved, cytisinicline would be the first new medicine approved by the FDA [...]
Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
09/11/2026
Data to highlight PTC-2105’s attenuation of terminal lean-mass decline and semaglutide-associated lean-mass loss in aged mice PTC-2105 is Eos’s lead clinical candidate in development for elderly patients with Sarcopenia [...]
DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases
09/11/2026
The collaboration combines DeepLife's AI virtual-cell platform, TwinCell, with 3billion's genomics and AI-driven medicinal chemistry technology, to create an end-to-end engine for discovering genetic modifier targets [...]
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
09/11/2026
Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results [...]
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
09/11/2026
New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for clinical laboratories [...]
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
09/11/2026
Deal valued at more than $140 million in upfront and potential milestone payments, plus double-digit royalties. Kyorin obtains exclusive rights to develop and commercialize paridiprubart, an anti-TLR4 monoclonal [...]
Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer
09/11/2026
CAMBRIDGE, UK and MONTREAL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been [...]
Epitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancé
09/11/2026
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 09 nov. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société de biotechnologie au stade clinique développant des vaccins anticancéreux prêts à l’emploi et durables à base d’ARN, a annoncé [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
09/11/2026
Tokyo, Japan and Cambridge, UK, 9 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum